Stay updated with breaking news from Sam Fisch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MIAMI, Dec. 14, 2023 -- Veru Inc. , a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology and viral-induced acute...
Operator: Good morning, ladies and gentlemen, and welcome to Veru Inc. Investor Conference Call. All participants will be in listen-only mode.
Operator: Good morning ladies and gentlemen, and welcome to Veru Inc.'s Investor Conference Call. All participants will be in listen-only mode.
Call End: Veru Inc. (NASDAQ:NASDAQ:VERU) Q2 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Samuel Fisch - Executive Director, Investor Relations and Corporate...
Share: -- Presentation of Phase 2 trial clinical trial data from patients with AR+ER+HER2- metastatic breast cancer demonstrating that the antitumor efficacy of enobosarm, a selective androgen receptor targeting agent, treatment is dependent on the magnitude of expression of androgen receptor (AR) in breast cancer tissue -- -- Presentation of Phase 1b/2 updated clinical trial results of sabizabulin (VERU-111), an oral androgen receptor transport disruptor, in metastatic castration and androgen receptor targeting agent resistant prostate cancer -- MIAMI, May 24, 2021 (GLOBE NEWSWIRE) -- Veru...